• SPX
  • $5,737.47
  • 0.43 %
  • $24.78
  • DJI
  • $41,917.19
  • 0.29 %
  • $122.58
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.08
  • -0.32 %
  • -$26.16
  • IXIC
  • $18,299.63
  • 0.66 %
  • $119.64
Cytokinetics, Incorporated (CYTK) Stock Price, News & Analysis

Cytokinetics, Incorporated (CYTK) Stock Price, News & Analysis

Currency in USD Disclaimer

$51.18

-$0.3

(-0.58%)

Day's range
$50.91
Day's range
$51.32
50-day range
$50.53
Day's range
$58.68
  • Country: US
  • ISIN: US23282W6057
52 wk range
$30.68
Day's range
$110.25


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.05
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (CYTK)
  • Company Cytokinetics, Incorporated
  • Price $51.18
  • Changes Percentage (-0.58%)
  • Change -$0.3
  • Day Low $50.91
  • Day High $51.32
  • Year High $110.25

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $85.00
  • High Stock Price Target $120.00
  • Low Stock Price Target $45.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.40
  • Trailing P/E Ratio -9.78
  • Forward P/E Ratio -9.78
  • P/E Growth -9.78
  • Net Income $-526,244,000

Income Statement

Quarterly

Annual

Latest News of CYTK

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.